Orbis Medicines uses its n Gen platform to design and synthesize oral macrocyclic compounds (n Cycles) that can engage both intra‑ and extracellular protein targets. The high‑throughput, AI‑enhanced workflow generates up to 100,000 candidate molecules per design cycle and screens them for oral bioavailability and membrane permeability. This approach aims to replace injectable biologics with orally administered drugs, expanding treatment options for patients.
Funding
$133.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing orally bioavailable macrocycle drugs is challenging due to the difficulty of achieving the necessary membrane permeability and bioavailability for effective targeting of both intracellular and extracellular proteins. Traditional de novo design methods have struggled to systematically produce therapeutically successful macrocycles with these properties.
Solution
Orbis Medicines utilizes its nGen platform to overcome the limitations of traditional macrocycle drug discovery. The nGen platform systematically explores macrocycle chemical space, generating and testing up to 100,000 unique oral macrocycle candidates (nCycles) optimized for oral bioavailability and membrane permeability. This high-throughput approach, combined with a DNA-encoded library of nearly 100 billion compounds, enables the identification of nCycle candidates suitable for both intra- and extracellular targets. The platform's design-make-test-analyze cycle generates a rich data footprint for each compound, potentially de-risking and accelerating development. Orbis leverages in-house deep learning capabilities to further enhance the platform and accelerate the future of macrocycle medicine.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing oral drugs against targets validated by biologics, as well as those exploring novel therapeutic areas with both intra- and extracellular targets.
Features
- nGen platform for high-throughput generation and testing of macrocyclic compounds
- Proprietary DNA-encoded libraries of nearly 100 billion compounds for hit identification
- nCycles: Oral macrocycle drug candidates optimized for bioavailability and membrane permeability
- Ability to target both intra- and extracellular proteins
- Design-make-test-analyze cycle generating up to 100,000 unique target-specific nCycles
- Full suite of assays for comprehensive compound testing
- Integration of automation for massively parallel library creation and assaying
- In-house deep learning capabilities for data analysis and platform enhancement